The move clears the way for millions of teenagers to receive an additional shot, with a top regulator citing evidence that the effectiveness of two doses is waning in the age group.The move clears the way for millions of teenagers to receive an additional shot, with a top regulator citing evidence that the effectiveness of two doses is waning in the age group.Food and Drug Administration, Pfizer Inc, BioNTech SE, Vaccination and Immunization, Coronavirus (2019-nCoV), Coronavirus Omicron Variant, Regulation and Deregulation of Industry, United States Politics and GovernmentRead More
